Quantcast
Last updated on April 19, 2014 at 18:42 EDT

Latest IsoRay Inc. Stories

2013-05-21 08:30:41

IASIS MEDICAL Sees Substantial Opportunity In Offering IsoRay's Entire Product Line RICHLAND, Wash., May 21, 2013 /PRNewswire/ -- IsoRay, Inc. (AMEX: ISR), (http://www.isoray.com/), announced today that it has entered into an exclusive international distribution agreement with IASIS Medical for the sale of IsoRay's complete product line in Greece. IsoRay is a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for brain cancer, lung...

2013-02-27 16:27:13

RICHLAND, Wash., Feb. 27, 2013 /PRNewswire/ -- IsoRay, Inc. (NYSE MKT: ISR) ("IsoRay" or the "Company"), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, released the following statement today. In view of the unusual market activity in IsoRay's common stock on February 26 and 27, 2013, the New York Stock Exchange has contacted the Company in accordance with its usual practice. IsoRay stated that its policy is not to comment on unusual...

2013-02-05 08:36:24

RICHLAND, Wash., Feb. 5, 2013 /PRNewswire/ -- IsoRay Inc. (AMEX: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced the presentation video by Cornell Weill demonstrating their techniques in the successful treatment of metastatic brain cancers using IsoRay's patented Cesium-131 (Cs-131) sutured seeds. Dr. Theodore H. Schwartz and Dr. Gabriella Wernicke, both of Weill Cornell Medical Center, presented their findings...

2011-12-05 09:08:00

NEW YORK, Dec. 5, 2011 /PRNewswire/ -- IsoRay, Inc. (AMEX: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for brain cancer, lung cancer, head and neck cancer and prostate cancer today announced that their December 1st RetailInvestorConferences.com presentation is now available for on-demand viewing. LINK: www.retailinvestorconferences.com > Click the red "register/ watch event now" button. IsoRay Inc.'s...

2011-12-02 19:32:00

<font size="2" face="Arial"> </font> LOS ANGELES, Dec. 2, 2011 /PRNewswire/ -- WestPark Capital, Inc. announced the completion of a public offering for IsoRay, Inc. (NYSE Amex: ISR). A total of 2,817,988 shares of common stock and warrants to purchase up to 563,598 shares of common stock were sold, generating gross proceeds of $2,592,549 in the offering. Proceeds from the offering will be used to fund new applications for IsoRay's Cesium-131 technology to treat lung, head...

2011-12-02 08:30:00

LOS ANGELES, December 2, 2011 /PRNewswire/ -- WestPark Capital, Inc. announced the completion of a public offering for IsoRay, Inc. (NYSE Amex: ISR). A total of 2,817,988 shares of common stock and warrants to purchase up to 563,598 shares of common stock were sold, generating gross proceeds of $2,592,549 in the offering. Proceeds from the offering will be used to fund new applications for IsoRay's Cesium-131 technology to treat lung, head and neck, breast and brain cancers, and for...

2011-11-29 09:08:00

NEW YORK, Nov. 29, 2011 /PRNewswire/ -- IsoRay, Inc. (AMEX: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for brain cancer, lung cancer, head and neck cancer and prostate cancer today announced that Dwight Babcock, Chairman and Chief Executive Officer, will co-present at RetailInvestorConferences.com. DATE: December 1, 2011 TIME: 5:00 PM EST LINK: www.retailinvestorconferences.com > Click the red...

2008-11-13 09:00:37

IsoRay Inc. (AMEX:ISR) a medical isotope company focusing on the treatment of prostate and other malignant disease through use of its proprietary radioisotope technology, today announced its financial results for the first quarter ended September 30, 2008. IsoRay Chairman and Interim CEO Dwight Babcock said sales revenue for the quarter decreased by 18 percent to approximately $1,519,583 as compared to approximately $1,855,719 in the year-earlier period. However, medical centers ordering...

2008-11-06 09:00:45

IsoRay Inc. (AMEX:ISR), a medical isotope company focused on the treatment of prostate cancer and other malignant disease through use of its proprietary radioisotope technology, announced today it will release first quarter results on Thursday, November 13, 2008, before market opening. That same day, at 4:30 p.m. ET, management will host a conference call, which will be broadcast live over the Internet. Participants should dial into the call 10-15 minutes before the scheduled time using...

2008-08-20 09:01:30

IsoRay Inc. (AMEX:ISR), a medical isotope company focused on the treatment of prostate cancer and other malignant disease through use of its proprietary radioisotope technology, announces today its financial results for the quarter and year ended June 30, 2008. "This year has seen many changes at IsoRay," said IsoRay Chairman and CEO Dwight Babcock. "We have made significant steps in focusing on the core business, gaining efficiencies, lowering the cost structure, and reducing cash...